Arcus Biosciences Accounts Payables 2011-2026 | RCUS

Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.

Main types of accounts payable

Type of liability	Example
To suppliers and contractors	Goods received but not yet paid for
Taxes and fees	VAT, income tax, etc., not paid on time
Salaries	Employee wages not paid
To budgets	Insurance contributions to funds not paid
To founders	Founders provided borrowed funds
To banks	Overdue loan payments
Other	Fines, penalties, forfeits, customer prepayments, etc.

Impact on the company's financial performance

Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios
Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence
Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals)
Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated

Annual Accounts Payables Arcus Biosciences

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
42 M	18 M	17 M	20 M	10 M	15.7 M	4.7 M	3.1 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
42 M	3.1 M	16.3 M

Quarterly Accounts Payables Arcus Biosciences

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
29 M	22 M	18 M	13 M	15 M	16 M	17 M	17 M	12 M	28 M	20 M	10.5 M	-	18.1 M	10.3 M	13.2 M	17 M	24.5 M	15.7 M	15.7 M	15.7 M	15.7 M	4.7 M	4.7 M	4.7 M	4.7 M	3.1 M	3.1 M	3.1 M	3.1 M	3.82 M	3.82 M	3.82 M	3.82 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
29 M	3.1 M	12.4 M

Accounts Payables of other stocks in the Biotechnology industry

Issuer	Accounts Payables	Price	% 24h	Market Cap	Country
I-Mab IMAB	570 M	-	-	$ 866 M	China
Apellis Pharmaceuticals APLS	56.8 M	$ 20.22	-2.32 %	$ 2.55 B	USA
Aptorum Group Limited APM	3.24 M	$ 0.82	-3.48 %	$ 4.47 M	China
Axsome Therapeutics AXSM	65.5 M	$ 164.71	-1.01 %	$ 8.19 B	USA
Catalyst Pharmaceuticals CPRX	11.2 M	$ 23.88	-	$ 2.92 B	USA
Corvus Pharmaceuticals CRVS	1.52 M	$ 18.08	1.06 %	$ 868 M	USA
Adverum Biotechnologies ADVM	1.61 M	-	-	$ 86.2 M	USA
Certara CERT	3.43 M	$ 7.19	1.93 %	$ 1.15 B	USA
Eton Pharmaceuticals ETON	1.85 M	$ 17.72	-2.37 %	$ 454 M	USA
Exelixis EXEL	29.6 M	$ 40.99	-0.1 %	$ 11.1 B	USA
ARCA biopharma ABIO	3.46 M	-	1052.0 %	$ 415 M	USA
Acer Therapeutics ACER	3.81 M	-	2.71 %	$ 14 M	USA
Alpine Immune Sciences ALPN	4.29 M	-	-	$ 2.17 B	USA
Acorda Therapeutics ACOR	13.4 M	-	-24.86 %	$ 820 K	USA
Greenwich LifeSciences GLSI	221 K	$ 27.7	1.12 %	$ 361 M	USA
Capricor Therapeutics CAPR	183 K	$ 26.04	-3.07 %	$ 697 M	USA
Acasti Pharma ACST	601 K	-	4.01 %	$ 150 M	Canada
Codexis CDXS	2.84 M	$ 0.99	-2.92 %	$ 72.7 M	USA
Halozyme Therapeutics HALO	20.9 M	$ 69.39	-0.67 %	$ 8.32 B	USA
Harmony Biosciences Holdings HRMY	17.7 M	$ 28.56	-1.19 %	$ 1.64 B	USA
ImmuCell Corporation ICCC	300 K	$ 6.3	-3.67 %	$ 51.5 M	USA
AgeX Therapeutics AGE	1.41 M	-	-10.17 %	$ 12.2 K	USA
Immunic IMUX	10.1 M	$ 1.1	3.3 %	$ 171 M	USA
Immunovant IMVT	17.7 M	$ 26.99	-2.74 %	$ 4.09 B	USA
Aeglea BioTherapeutics AGLE	677 K	-	-	$ 1.01 B	USA
Inhibrx INBX	11 M	$ 75.96	-1.97 %	$ 3.58 B	USA
InMed Pharmaceuticals INM	544 K	$ 0.75	-8.49 %	$ 1.84 M	Canada
INmune Bio INMB	199 K	$ 1.41	6.07 %	$ 25.4 M	USA
Insmed Incorporated INSM	79.9 M	$ 146.89	0.39 %	$ 29.2 B	USA
Applied Genetic Technologies Corporation AGTC	2.91 M	-	-	$ 26.5 M	USA
Agenus AGEN	61.4 M	$ 3.19	-4.49 %	$ 1.14 M	USA
Ayala Pharmaceuticals AYLA	4.08 M	-	-	$ 7.46 M	Israel
Akero Therapeutics AKRO	9.03 M	-	-	$ 3.67 B	USA
Agios Pharmaceuticals AGIO	18.4 M	$ 29.11	-0.31 %	$ 1.69 B	USA